Sasaki Ken, Natsugoe Shoji, Aridome Kuniaki, Ishigami Sumiya, Hokita Shuichi, Aikou Takashi
Department of Surgical Oncology and Digestive Surgery, Kagoshima University School of Medicine, Kagoshima, Japan.
Hepatogastroenterology. 2007 Dec;54(80):2421-4.
We report the case of 67-year-old man who was given a diagnosis of advanced gastric adenocarcinoma. Complete response of multiple liver and paraaortic lymph node metastases occurred in this patient after combination chemotherapy with systemic injection of paclitaxel and oral administration of novel dihydropyrimidine- dehydrogenase- inhibitory fluoropyrimidine (S-1). Following 7 courses of the biweekly paclitaxel and S-1 combination chemotherapy, the patient underwent total gastrectomy with D3 extended lymph node dissection. According to the operative findings, the tumor was curatively removed along with the liver metastases and paraaortic lymph node metastases. Biopsy of the liver was performed and the pathological diagnosis indicated no gastric adenocarcinoma cells. The pathological report showed that the lymph node metastases had completely disappeared with single exception and minute cancerous lesions were identified in the gastric mucosa and submucosa. Therefore, the histological efficacy was evaluated as Grade 2. For postoperative chemotherapy, oral S-1 administration only was chosen. However, 6 months later, biweekly paclitaxel and S-1 combination chemotherapy was administered in sequence as a second adjuvant chemotherapy because the serum level of the tumor marker was elevated. The patient is fine and has not shown any recurrence at other sites 37 months after surgery. Salvage surgery following paclitaxel and S-1 chemotherapy may be feasible for patients with advanced gastric cancer and complete regression of distant metastases. Biweekly paclitaxel and S-1 combination chemotherapy has been used safely and its administration may be continued for a long time in an outpatient clinic setting for the treatment of advanced gastric cancer.
我们报告了一例67岁男性患者,其被诊断为晚期胃腺癌。该患者在接受全身注射紫杉醇和口服新型二氢嘧啶脱氢酶抑制性氟嘧啶(S-1)联合化疗后,多发肝转移和腹主动脉旁淋巴结转移出现了完全缓解。在接受7个疗程的每两周一次的紫杉醇和S-1联合化疗后,患者接受了D3扩大淋巴结清扫的全胃切除术。根据手术所见,肿瘤连同肝转移灶和腹主动脉旁淋巴结转移灶被根治性切除。对肝脏进行了活检,病理诊断显示无胃腺癌细胞。病理报告显示,除单个例外,淋巴结转移已完全消失,且在胃黏膜和黏膜下层发现了微小癌灶。因此,组织学疗效评估为2级。对于术后化疗,仅选择口服S-1。然而,6个月后,由于肿瘤标志物血清水平升高,每两周一次的紫杉醇和S-1联合化疗作为第二辅助化疗依次进行。患者状况良好,术后37个月未出现其他部位复发。对于晚期胃癌且远处转移完全消退的患者,紫杉醇和S-1化疗后的挽救性手术可能是可行的。每两周一次的紫杉醇和S-1联合化疗已安全使用,并且在门诊环境中可长期持续给药用于治疗晚期胃癌。